U.S., June 6 -- ClinicalTrials.gov registry received information related to the study (NCT07629115) titled 'A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.' on May 12.
Brief Summary: The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.
Study Start Date: June 30
Study Type: OBSERVATIONAL
Condition:
Parkinson Disease
Parkinson's Disease
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Innopeutics Corporation
Disclaimer: Curated by HT Syndication....